

Launch of research-use-only adenovirus F41 assay

RNS Number : 0025U

Novacyt S.A.

28 July 2022

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Launch of research-use-only adenovirus F41 assay

The assay has been developed by Novacyt to support research efforts following a recent increase in cases of acute hepatitis in children

Paris, France and Camberley, UK - 28 July 2022 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of a research-use-only (RUO) polymerase chain reaction (PCR) assay for the detection of adenovirus F41, in response to recent cases of acute hepatitis in children. This launch expands Novacyt's genesig® real-time PCR diagnostic product portfolio and is in line with the Company's strategy to maintain its position as a global first responder in infectious diseases.

Adenoviruses are a large group of viruses divided into several species and subtypes. They are the cause of several illnesses, usually exhibiting as colds or flu-like illness, which may also cause gastrointestinal symptoms such as diarrhoea. Adenoviruses are primarily spread via respiratory droplets; however, they can also be spread by faecal routes. Ongoing investigations, particularly in the UK, have identified adenovirus infection in children, and in particular, adenovirus F41 in several cases.

This assay has been developed in two forms, genesig® Advanced and genesig® Easy, designed for in vitro detection of adenovirus species F serotype 41 genomes, without detecting any closely related adenovirus sequences. Novacyt's genesig® Advanced assay is configured for use with any open test platform, including Novacyt's MyGo instruments, the genesig® Easy assay is suitable for use on the Company's q16 and q32 instruments.

Novacyt, through its specialist bioinformatics surveillance expertise, continually tracks the changing pathology of diseases worldwide, and will regularly review the detection profile of assays, ensuring that new versions are developed if necessary.

David Allmond, Chief Executive Officer of Novacyt, commented:

"Our RUO adenovirus F41 assay has been developed in response to recent cases of acute hepatitis in children to support research efforts in determining the cause of this severe disease. The launch of this new assay, as well as our recent assay for the detection of the Monkeypox virus, subsequently declared a global health emergency by the WHO, reinforce Novacyt's position as a global first responder, as well as our commitment to expanding our portfolio in infectious diseases, both in line with our stated strategy. Our extensive leading RUO portfolio consists of over 850 products, spanning veterinary, food, environment, and human health research. The portfolio is a key part of our core business and serves as an innovation engine for the Company as we transition beyond the Covid-19 pandemic."

- End -

Contacts

Novacyt SA

David Allmond, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

+44 (0)20 7260 1000

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com/ y.petit@allegrafinance.com

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / Alex.Shaw@fticonsulting.com / Novacyt.group@fticonsulting.com

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company supplies an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates

For more information, please refer to the website: www.novacyt.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRARRMBTMTTTLT